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Material & methods: We studied blood and sputum samples from stable COPD
patients (mean FEV1 60.577.5% predicted) at baseline (no treatment) and after 10
weeks treatment with either inhaled steroid, fluticasone propionate (FP) (1000 mg/d)
or 10 weeks treatment with N-acetylcysteine (600mg/d) (NAC). We assessed the
inflammatory markers (IL-8, ECP, sICAM-1, NE) in sputum and serum and we
compared them with blood markers of oxidative stress (SOD, GPx, TEAC, albumin,
vitamin E and A).
Results: At baseline blood sICAM-1 correlated with IL-8 levels (Po0:01; r ¼ 0:62)
and negatively with GPx (Po0:01; r ¼ 0:63) and with TEAC (Po0:05; r ¼ 0:53).
TEAC correlated positively with GPx (Po0:01; r ¼ 0:70).4 Elsevier Ltd. All rights reserved.
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A.M. Sadowska et al.242Correlation between sICAM and IL-8 disappeared after NAC treatment. The
correlation between sICAM and GPx disappeared after FP treatment. The correlation
between TEAC and GPx was maintained after both NAC and FP.
Conclusions: The relationship between markers of inflammation, adhesion and
antioxidant capacity is significantly modulated by treatment with N-acetylcysteine
or inhaled corticosteroids.
r 2004 Elsevier Ltd. All rights reserved.Introduction
The pathogenesis of chronic obstructive pulmonary
disease (COPD) is complex. It involves both airway
inflammation1 and an oxidant/antioxidant imbal-
ance.2 The inflammatory response is usually ac-
companied by an influx of neutrophils and release
of proteases (neutrophil elastase, tryptase) and
reactive oxygen species. Excessive transmigration
is responsible for the enhanced number of neutro-
phils that is found in the airways and in a
bronchoalveolar lavage fluid (BAL) of COPD pa-
tients.3 During this transmigration process various
mediators are released. These involve cytokines
that regulate the expression of adhesion molecules,
inflammatory cell degranulation and migration.4
This inflammatory process is also accompanied by
oxidative stress. Proinflammatory cytokines and
growth factors stimulate release of reactive oxygen
species (ROS) which act as signalling mediators for
a variety of signal transduction pathways and gene
expression.5–7 The transcription factors that have
been implicated in many inflammatory responses
are the nuclear factor-kappa B (NF-kB) and
activator protein-1 (AP-1).8,9 Both NF-kB and AP-1
are sensitive to many different oxidative stress
stimuli and some findings suggest that they may
mediate cytokine and adhesion molecules expres-
sion.10,11 Moreover, NF-kB is reported to be
inhibited by antioxidants like N-acetylcysteine
(NAC)5,12 and it could be also influenced by
steroids.13 These observations suggest that inflam-
mation and oxidative stress are co-dependent and
strongly interrelated processes.
In order to characterise this interrelationship in
COPD we assessed the correlation between the
antioxidant defence markers (superoxide dismutase
(SOD), glutathione peroxidase (GPx), trolox equiva-
lent antioxidant capacity (TEAC), vitamin E and A),
inflammation markers (intercellular adhesion mo-
lecule-1 (ICAM-1), interleukin-8 (IL-8), eosinophil
cationic protein (ECP) and neutrophil elastase (NE).
We also aimed to study the changes in the
relationships after treatment with NAC or flutica-
sone propionate (FP) by analysing these interrela-
tionships at baseline and after a 10-week period of
treatment. This duration of treatment is based onstudies which have demonstrated that treatments
of at least 8 weeks inhaled steroids are required
before the in vivo and anti-inflammatory effects
become manifest.14,15Materials and methods
Twenty patients (16 male, 4 female) were recruited
at The National Institute of Tuberculosis and Lung
Diseases, Warsaw, Poland. Inclusion criteria were:
smoker or ex-smoker, not fully reversible airway
obstruction with 50%oFEV1o80% and chest X-ray
compatible with COPD. Patients with any history of
atopy, asthma, renal and/or hepatic failure, major
cardiac disease, cystic fibrosis, as well as patients
who suffered an exacerbation of COPD in the last
three months or used non-steroid anti-inflamma-
tory medication, theophylline, long-acting beta
stimulants or oxygen therapy were excluded from
the study.
Study design
The study consisted of 4 periods of 10 weeks each
and involved five visits. After a first 10-week period
of wash-out, patients were randomised in a double
blind manner to two groups. The first group
(n ¼ 10) received oral NAC (Lysomucils, Zambon,
Poland) (600mg, once a day) in combination with
placebo for FP for 10 weeks. The second group
(n ¼ 10) received placebo for NAC with inhaled FP
via dry powder inhaler (DPI) (GSK, Poland) (1000 mg
in two daily dosages of 500 mg). This was followed
by a second wash-out period of 10 weeks; where
after there was a cross-over to the alternative
regime. Only short-acting beta agonists and/or
anticholinergics (salbutamol or fenoterol and/or
ipratropium bromide) were allowed during the
whole period of the study. Patients were withdrawn
from the study if they were treated with anti-
inflammatory agents and/or oral steroids and/or
theophylline. In case of acute exacerbation of
COPD (AE) requiring treatment with an antibiotic,
the observation period was prolonged for further
two weeks after stopping with the antibiotic.16
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fasting blood samples were collected and spirome-
try was performed to assess clinical stability.Spirometry and sputum induction
FEV1 measurements were performed before and
10min after inhalation of 200 mg salbutamol. After
spirometry, subjects inhaled 4.5% hypertonic saline
aerosol, generated by a nebuliser (De Vilbiss,
Somerset, PA, USA) during three periods of 5min
each. Following each period of hypertonic inhala-
tion, subjects were asked to rinse their mouth and
encouraged to cough and expectorate sputum into
a sterile plastic container which was kept on ice.
The procedure was stopped after three periods of
5min or after a fall in FEV1 20% or more from the
baseline.Sputum processing
Sputum was processed within 2 h of collection. The
weight of sputum plugs was determined and
Sputolysins (Calbiochem, CA, USA) (diluted 1:10
in PBS (Dulbecco’s Phosphate Buffered Saline)
(Invitrogen, Paisley, UK)) added in a volume (ml)
equal to 4 times the selected sample weight (mg).
The samples were then mixed for 30 s on a mixer
and further broken down by aspirating and dispen-
sing several times with a disposable pipette. Then
they were placed on a bench tube rocker for 15min
at 22 1C. The samples were then filtered through a
48 mm nylon mesh (Cell Streiner, Becton Dickinson,
Franklin Lakes, NJ, USA) in to a pre-weighted
conical tube. Total cell count and viability were
checked by trypan blue exclusion. The filtered
samples were centrifuged at 500g at 22 1C for
10min. The supernatant was aspirated and stored
at 80 1C. The cell pellet was resuspended in PBS
to a concentration of 1 106 cells/ml and four
cytospin slides were stained according to May-
Grunwald-Giemsa (MGG). Differential cell count
was performed by counting 400 cells in a blind way.
Blood samples were collected into sterile tubes
containing either lithium-heparin or a clotting
activator gel (S-Monovette System, 7.5ml, Sar-
stedt, Nu¨mbrecht, Germany).
Trolox equivalent antioxidant capacity (TEAC)
was measured spectrophotometrically in plasma at
the wavelength 734 nm using the method of Re
et al.17 TEAC value was calculated by means of the
Trolox standard curve (% decolorisation vs. Trolox
concentration).
Glutathione peroxidase (GPx) in full blood was
measured with a Ransel Glutathione Peroxidase kit(Randox Laboratories Ltd., Antrim, UK) and is based
on the method of Paglia and Valentine.18
Superoxide dismutase in red blood cells was
measured with RanSOD superoxide dismutase kit
(Randox Laboratories Ltd., Antrim, UK).
Albumin in sputum and serum was measured
according to the method of Doumas et al.19
Alpha-tocoferol and retinol in serum were
measured by High Performance Liquid Chromato-
graphy (Dionex, HPLC with a 100% methanol mobile
phase) with detection at 292 and 325 nm, respec-
tively, and a coefficient of variance (CV) of 10% and
13%, respectively.20
Eosinophil cationic protein (ECP) was measured
in serum and sputum using a fluoroenzymeimmu-
noassay provided by Pharmacia & Upjohn (Uppsala,
Sweden). The assay is performed on UniCAP 100
instrument.
Tryptase was measured in sputum and serum
applying the immunoassay from Pharmacia &
Upjohn, according to the same principle as
described for ECP.
Neutrophil elastase (NE) activity present in
sputum and serum samples was measured spectro-
photometrically using the synthetic substrate
methoxysuccinyl-ala-ala-pro-val-paranitroanilide
(MeOSAAPVpNa) (Sigma Chemicals, Bornem, Bel-
gium). Aliquots of 50 ml of standard or sample were
added to wells of a microtiter plate (Life Technol-
ogies, Ltd., Paisley, UK) followed by MeOSAAPVpNa
solution. The reaction was continued for 20 h at
37 1C. The absorbance was read at 405 nm.21
Soluble ICAM-1 in sputum and serum was mea-
sured with ELISA: test plate Human sICAM-1,
Biosource International, Camarillo, USA). The valid
analytical range is 0.625–10 ng/ml.
Interleukin-8 and 10 in both sputum and serum
were measured with Flexiat, Biosource Interna-
tional, Camarillo, USA. Valid analytical range of IL-
8 is 3.6–750 pg/ml and of IL-10 is 6–1000 pg/ml).
Statistical analysis
The Pearson correlation coefficient was used to test
for correlation between parameters. Statistical
significance was assumed when the two-tailed P
value was less than 0.05. Data were analysed using
Statistica 5.1, StatSoft, Inc., Tulsa, OK, USA.Results
The results present an analysis of 20 patients who
provided adequate samples at each visit. Two
patients dropped out after the fourth visit (the
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A.M. Sadowska et al.244second wash-out period): one because of protocol
violation and the other one due to prolonged
exacerbation of COPD. Three patients (included in
the analysis) experienced AE of COPD (one of them
during FP, two during NAC treatment). The subject
characteristics are given in Table 1. Parameters
were not significantly different after each wash-out
period. All patients were studied in the stable
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serum ICAM-1(ng/ml)
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Lung function at baseline
At baseline, there was no correlation between lung
function (FEV1% predicted) and any of the inflam-
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(B)Correlation between markers of
inflammation
At baseline was a positive correlation between
serum sICAM-1 and serum IL-8 levels (Po0:01;
r ¼ 0:62). This correlation was maintained after
FP (Po0:01; r ¼ 0:65) but disappeared after NAC
treatment (P ¼ 0:38; r ¼ 0:22) (Figs. 1A–C). There
was no correlation between NE and the other
markers. Moreover, there was no correlation
between neutrophil numbers and any of the
markers in the induced sputum. The sputum
markers were measurable within the accepted
ranges of the kits (for example, ICAM-1 in sputum
values ranged from 0.68 to 10 ng/ml, IL-8 from 23
to 3000 pg/ml and ECP from 2 to 1350 ng/ml).Table 1 Patient’s characteristics at visit 0.
Characteristics
Number of patients (n) 20
Age (years) 64.672.1
Sex (male/female)a 16/4
BMI (kg/m2) 25.671.1
Current smokers/ex-smokersa 11/9
Smoking (packyears) 36.773.7
FEV1 (% predicted) 60.571.7
FEV1 (% predicted) post-salb 65.172.6
FVC (% predicted) 84.172.6
FVC (% predicted) post-salb 87.972.8
FEV1/FVC 54.172.3
FEV1/FVC post-salb 55.272.6
Data are presented as mean7SEM. n=number of patients,
FEV1: forced expiratory volume in 1 s, FVC: forced vital
capacity, post salb: after salbutamol administration
(200mg).
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Figure 1 Relationship between serum interleukin-8 and
serum intercellular adhesion molecule-1: (A) at baseline,
(B) after treatment with FP, and (C) after treatment with
NAC.Correlation between inflammatory and
oxidative stress markers
At baseline serum sICAM-1 correlated negatively
with GPx (Po0:01; r ¼ 0:63). This was maintained
after NAC treatment period (Po0:01; r ¼ 0:67)
but not after FP (P ¼ 0:15; r ¼ 0:35) (Fig. 2A–C).
Serum sICAM-1 also correlated negatively with
TEAC at baseline (Po0:05; r ¼ 0:57) as well as
after FP (Po0:05; r ¼ 0:50) and NAC (Po0:01;
r ¼ 0:69) treatment periods.
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Figure 2 Relationship between serum intercellular adhe-
sion molecule-1 and glutathione peroxidase: (A) at
baseline, (B) after treatment with FP, and (C) after
treatment with NAC.
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Figure 3 Relationship between serum interleukin-8 and
glutathione peroxidase: (A) at baseline, (B) after treat-
ment with FP, and (C) after treatment with NAC.
Interrelationship in COPD 245Moreover, serum IL-8 levels correlated negatively
with GPx (Po0:05; r ¼ 0:45) and TEAC (Po0:05;
r ¼ 0:52) at baseline. Serum IL-8 correlated
negatively with GPx and TEAC after FP (Po0:05;
r ¼ 0:47 and Po0:05; r ¼ 0:50; respectively) but
not after NAC treatment (Figs. 3 and 4A–C).Correlation between oxidative stress
markers
TEAC correlated positively with GPx during all
periods: at baseline (Po0:01; r ¼ 0:7), after FP(Po0:001; r ¼ 0:77) and after NAC (Po0:05;
r ¼ 0:52) (Figs. 5A–C).
There are no correlations between SOD, albumin,
retinol and tocoferol and the inflammatory markers
(data not shown).Discussion
This study analyses the correlations between
inflammatory and oxidative stress markers in stable
COPD patients receiving no anti-inflammatory
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Figure 4 Relationship between serum interleukin-8 and
Trolox equivalent antioxidant capacity: (A) at baseline,
(B) after treatment with FP, and (C) after treatment with
NAC.
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Figure 5 Relationship between glutathione peroxidase
and Trolox equivalent antioxidant capacity: (A) at base-
line, (B) after treatment with FP, and (C) after treatment
with NAC.
A.M. Sadowska et al.246treatment or after treatment with an anti-oxidant
(NAC) or an inhaled corticosteroid (FP). Previous
studies have shown that ROS released from circu-
lating neutrophils is associated with the develop-
ment of the airflow limitation in COPD patients.22
The pathogenic mechanisms explaining this asso-
ciation are multifactorial and involve an intricate
interplay between inflammatory and oxidative
processes. On the one hand, these ROS, by
activating NF-kB and other redox-sensitive tran-
scription factors such as AP-1, cause an increasedgene expression of both pro-inflammatory cyto-
kines and of protective enzymes. On the other
hand, these cytokines play an important role as
activators of neutrophils and as chemoattrac-
tants,23 which will, in their turn, determine the
mediators released from neutrophils. The correla-
tion we observed between ICAM-1 and IL-8 at
baseline supports the idea that inflammation,
which is reflected by increased IL-8 levels,
promotes the expression of adhesion molecules
(ICAM-1).24
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phils and chemoattractants is more complex
because IL-8 is released not only from neutrophils
but also from epithelial cells.25 Moreover, there is
also another important mediator leukotriene B4
(LTB4) that participates in the neutrophil re-
sponse.26 The lack of correlation between NE and
IL-8 observed in our study suggests that there are
multiple sources of IL-8 and that additional factors
play a role in NE and IL-8 release.
The relationship between inflammation and
oxidative stress indices is also complex. The
common factor for both pathways is NF-kB, which,
when activated, induces the expression of cyto-
kines and adhesion molecules in a positive feedback
loop. Moreover, this pathway is also redox-depen-
dent and is activated by oxidative stress. There-
fore, it can be postulated that antioxidant defence
capacity may affect inflammatory response. For
example, increased antioxidants in blood could, by
inhibiting NF-kB, lead to a decrease in both IL-8 and
ICAM-1 levels.27 In this study we assessed antiox-
idant defence by monitoring GPx, as example of an
antioxidant enzyme and TEAC, as example of the
non-enzymatic antioxidant capacity of plasma. The
strong positive correlation between TEAC and GPx
at all points during the study supports the fact that
these two antioxidant mechanisms are tightly
related. Moreover, GPx and TEAC correlated nega-
tively with blood levels of sICAM-1 and IL-8 at
baseline. These results support our hypothesis of a
negative feedback loop between antioxidant capa-
city and inflammatory response.
NAC, a thiol-containing compound, is known for
its antioxidant activity.28 By acting as a direct
scavenger of ROS it protects cells against damage
by H2O2. As a source of sulfhydryl groups in cells
and by increasing reduced glutathione levels in
cells, it decreases NF-kB activity, and neutrophil
hyperreactivity.
In our group of patients treatment with the
antioxidant NAC tended to decrease IL-8 levels but
did not affect TEAC, GPx or ICAM-1 (manuscript in
preparation). The change in IL-8 levels was accom-
panied by a disappearance of the negative correla-
tion between this pro-inflammatory cytokine and
GPx and TEAC. This suggests that NAC affected IL-8
expression by pathways not involving GPx and
plasma antioxidants.12 The disappearance of the
positive correlation between IL-8 and ICAM-1 after
NAC supports the concept that ICAM-1 expression is
additionally or even alternatively modulated by
pathways which are not dependent on NF-kB
activity and which are therefore not as susceptible
to the effects of NAC treatment as, for example, IL-
8.5 For example PKC, the IFN-g dependent JAK/STAT pathway and MAP kinases have all been shown
to act in concert and to co-activate ICAM-1
expression depending on the cell type and on the
type of stimulus.29 Some of these pathways (MAPK
and protein PKC) can be induced by IL-8 in human
neutrophils,30 but others are IL-8-independent.24
IL-8, in its turn, is regulated not only by activation
of the NF-kB transcription factor but also through
other pathways such as protein kinase A (PKA),
protein kinase C (PKC) and p38 mitogen activated
protein kinase (MAPK).31 This phenomenon of
multiple regulatory mechanisms can explain the
unequal down-regulation of IL-8 and ICAM-1 that
we observed after treatment with NAC. A similar
observation in sepsis patients was attributed to the
differences in the kinetics of the cytokine and
adhesion molecule since it takes longer for soluble
ICAM-1, which is shed by the endothelial cells, to
reach the blood circulation.32 And lastly, it is
plausible that the changes in redox status (GSH/
GSSG ratio) needed to affect NF-kB-dependent
transcription might be higher for ICAM-1 than for
IL-8, a phenomenon observed for E-selectin and
VCAM.33
In contrast to NAC, FP treatment which led to a
significant increase in antioxidant capacity (GPx
and TEAC) was accompanied by a loss of the
negative correlation of GPx with ICAM-1. FP did
not affect IL-8 or ICAM-1 levels and consequently
had no effect on the correlations between this
cytokine and ICAM-1 or antioxidants. This lack of
effect is in concordance with the observation that
FP might act through NF-kB-independent path-
ways.34,35 Recent literature shows that GPx is
regulated by AP-1.36
In summary, we assessed some of the relation-
ships between inflammatory markers and oxidative
stress markers and pointed out to significant
modulation of these interrelationships by treat-
ment with FP and NAC. Understanding the relation-
ship between these processes requires more studies
with specific inductors and inhibitors directed
against intracellular mediating pathways such as
p38 MAP kinase and NF-kB37 as well as antisense
oligonucleotides.38 Elucidating the processes be-
hind the inflammatory response in COPD and their
relation to oxidative stress may potentially con-
tribute to the development of preventive and
therapeutic strategies that will slow down the
process of lung destruction.Acknowledgements
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